We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Nutra Pharma Corp (CE) | USOTC:NPHC | OTCMarkets | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.0001 | 0.0001 | 0.0001 | 0.0001 | 100,001 | 01:00:00 |
þ
|
QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.
|
o
|
TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT
|
California
|
91-2021600
|
|
(State or Other Jurisdiction of Organization)
|
(IRS Employer Identification Number)
|
12502 West Atlantic Blvd., Coral Springs, Florida
|
33071
|
|
(Address of principal executive offices)
|
(Zip Code)
|
Large accelerated filer
¨
|
Accelerated filer
¨
|
Non-accelerated filer
¨
|
Smaller reporting company
þ
|
PART I. FINANCIAL INFORMATION
|
1
|
Item 1. Financial Statements
|
1
|
Condensed Consolidated Balance Sheets as of March 31, 2014 (Unaudited) and December 31, 2013
|
F-1
|
Condensed Consolidated Statements of Operations for the Three Months Ended March 31, 2014 and 2013 (Unaudited)
|
F-2
|
Condensed Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2014 and 2013 (Unaudited)
|
F-3
|
Notes to Condensed Consolidated Financial Statements (Unaudited)
|
F-4
|
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
|
2
|
Item 3. Quantitative and Qualitative Disclosures about Market Risk
|
9
|
Item 4. Controls and Procedures
|
9
|
PART II. OTHER INFORMATION
|
9
|
Item 1. Legal Proceedings
|
9
|
Item 1A. Risk Factors
|
|
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
|
11
|
Item 3. Defaults Upon Senior Securities
|
12
|
Item 4. Mine Safety Disclosure
|
12
|
Item 5. Other Information
|
12
|
Item 6. Exhibits
|
12
|
NUTRA PHARMA CORP. |
Condensed Consolidated Balance Sheets
|
Current liabilities:
|
||||||||
Accounts payable
|
$ | 1,104,577 | $ | 1,019,130 | ||||
Accrued expenses
|
967,663 | 957,682 | ||||||
Due to officers
|
703,222 | 689,588 | ||||||
Derivative warrant liability
|
250,049 | 323,172 | ||||||
Other debt
|
1,018,996 | 1,359,238 | ||||||
Total current liabilities
|
4,044,507 | 4,348,810 | ||||||
Convertible debts
|
30,000 | - | ||||||
Total liabilities
|
4,074,507 | 4,348,810 | ||||||
Commitments and Contingencies (See Note 7)
|
- | - | ||||||
Stockholders' deficit:
|
||||||||
Common stock, $0.001 par value, 2,000,000,000 shares authorized;
1,062,274,057 and 1,004,313,019 shares issued and outstanding at March 31, 2014 and December 31, 2013
|
1,062,273 | 1,003,062 | ||||||
Additional paid-in capital
|
37,158,193 | 36,764,309 | ||||||
Accumulated deficit
|
(42,193,729 | ) | (41,986,820 | ) | ||||
Total stockholders' deficit
|
(3,973,263 | ) | (4,219,449 | ) | ||||
Total liabilities and stockholders' deficit
|
$ | 101,244 | $ | 129,361 |
See the accompanying notes to the condensed consolidated financial statements.
|
For the Three Months Ended March 31,
|
||||||||
2014
|
2013
|
|||||||
Net sales
|
$ | 54,753 | $ | 22,556 | ||||
Cost of sales
|
8,011 | 7,254 | ||||||
Gross profit
|
46,742 | 15,302 | ||||||
Operating expenses:
|
||||||||
Selling, general and administrative - including stock based
compensation of $44,552 and $195,327, respectively
|
274,688 | 347,150 | ||||||
Total other costs and expenses
|
274,688 | 347,150 | ||||||
Net Loss from Operations
|
(227,946 | ) | (331,848 | ) | ||||
Other Expenses
|
||||||||
Interest expense
|
(30,508 | ) | (39,213 | ) | ||||
Change in fair value of derivatives
|
51,545 | (37,199 | ) | |||||
Loss on settlement of debt and accounts payable, net
|
- | (65,039 | ) | |||||
21,037 | (141,451 | ) | ||||||
Net loss before income taxes
|
(206,909 | ) | (473,299 | ) | ||||
Provision for income taxes
|
- | - | ||||||
Net loss
|
$ | (206,909 | ) | $ | (473,299 | ) | ||
`
|
||||||||
Net loss per share - basic and diluted
|
$ | (0.00 | ) | $ | (0.00 | ) | ||
Weighted average number of shares outstanding during
the period - basic and diluted
|
1,024,480,984 | 578,614,296 |
See the accompanying notes to the condensed consolidated financial statements.
|
For the Three Months Ended March 31,
|
||||||||
2014
|
2013
|
|||||||
Cash flows from operating activities:
|
||||||||
Net loss
|
$ | (206,909 | ) | $ | (473,299 | ) | ||
Adjustments to reconcile net loss to net cash used in operating activities:
|
||||||||
Loss on settlement of accounts payable
|
- | 65,039 | ||||||
Depreciation and amortization
|
3,745 | 3,746 | ||||||
Stock-based compensation
|
44,552 | 195,327 | ||||||
Stock issued for loan extension
|
31,275 | - | ||||||
Change in fair value of derivative
|
(51,545 | ) | 37,199 | |||||
In-kind contribution of interest
|
- | 7,805 | ||||||
Changes in operating assets and liabilities:
|
||||||||
Increase in accounts receivables
|
(7,587 | ) | (5,917 | ) | ||||
Increase in prepaid expenses and other assets
|
(6,871 | ) | (6,429 | ) | ||||
Increase in accounts payable
|
85,447 | 90,077 | ||||||
Increase in accrued expenses
|
17,351 | 22,377 | ||||||
Net cash used in operating activities
|
(90,542 | ) | (64,075 | ) | ||||
Cash flows from investing activities:
|
- | - | ||||||
Cash flows from financing activities:
|
||||||||
Common stock sold for cash
|
60,000 | - | ||||||
Loans from officers
|
25,664 | 38,816 | ||||||
Repayment of officers loans
|
(19,400 | ) | (2,300 | ) | ||||
Proceeds from convertible notes
|
30,000 | 20,000 | ||||||
Net cash provided by financing activities
|
96,264 | 56,516 | ||||||
Net (decrease) increase in cash
|
5,722 | (7,559 | ) | |||||
Cash - beginning of period
|
4,640 | 7,559 | ||||||
Cash - end of period
|
$ | 10,362 | $ | - | ||||
Supplemental Cash Flow Information:
|
||||||||
Cash paid for interest
|
$ | 9,513 | $ | 12,417 | ||||
Cash paid for income taxes
|
$ | - | $ | - | ||||
Non cash Financing and Investing:
|
||||||||
Shares issued to satisfy debt
|
$ | 361,820 | $ | 120,543 |
See the accompanying notes to the condensed consolidated financial statements.
|
March 31, 2014
|
December 31, 2013
|
|||||||
Computer equipment
|
$ | 21,918 | $ | 21,918 | ||||
Furniture and fixtures
|
34,757 | 34,757 | ||||||
Lab equipment
|
42,129 | 42,129 | ||||||
Telephone equipment
|
12,421 | 12,421 | ||||||
Office equipment – other
|
2,629 | 2,629 | ||||||
Leasehold improvements
|
67,417 | 67,417 | ||||||
Total
|
181,271 | 181,271 | ||||||
Less: Accumulated depreciation and amortization
|
(160,482 | ) | (156,737 | ) | ||||
Property and equipment, net
|
$ | 20,789 | $ | 24,534 |
March 31, 2014
|
March 31, 2013
|
|||||||
Options and warrants
|
166,916,667 | 59,856,667 | ||||||
Convertible notes payable
|
69,187,476
|
86,517,657 | ||||||
Total
|
236,104,143 | 146,374,324 | ||||||
Fair Value Measurements at March 31, 2014
|
||||||||||||||||
Liabilities:
|
Total
|
Level 1
|
Level 2
|
Level 3
|
||||||||||||
Warrant liability
|
$ | 250,049 | $ | - | $ | - | $ | 250,049 | ||||||||
Convertible notes at fair value
|
$ | 456,814 | $ | - | $ | - | $ | 456,814 | ||||||||
Fair Value Measurements at December 31, 2013
|
||||||||||||||||
Liabilities:
|
Total
|
Level 1
|
Level 2
|
Level 3
|
||||||||||||
Warrant liability
|
$ | 323,172 | $ | - | $ | - | $ | 323,172 | ||||||||
Convertible notes at fair value
|
$ | 767,056 | $ | - | $ | - | $ | 767,056 |
Description
|
March 31, 2014
|
|||
Beginning balance
|
$ | 323,172 | ||
Purchases, issuances, and settlements
|
- | |||
Day one loss on value of hybrid instrument
|
- | |||
Total gain included in earnings (1)
|
(73,123 | ) | ||
Ending balance
|
$ | 250,049 |
Conversion Price - Lower of Fixed Price or Percentage of VWAP for Look-back Period
|
|||||||||||||||
Debenture
|
Face
|
Default
|
Anti-Dilution
|
Look-back
|
|||||||||||
Interest
|
Adjusted
|
||||||||||||||
Issuance Year
|
Amount
|
Interest Rate
|
Rate
|
Price
|
%
|
Period
|
|||||||||
2014
|
456,814
|
8%-
20%
|
n/a
|
$0.0033-
$0.0057
|
50%-
85%
|
10 to 30
Days
|
March 31, 2014
|
||||
Description
|
||||
Beginning balance
|
$ | 767,056 | ||
Purchases, issuances, and settlements
|
30,000 | |||
Day one loss on value of hybrid instrument
|
18,104 | |||
(Gain) loss from change in fair value
|
3,474 | |||
Conversion to common stock
|
(361,820 | ) | ||
Ending balance
|
$ | 456,814 |
March 31, 2014
|
December 31, 2013
|
|||||||
An unsecured demand loan from our President and CEO, Rik Deitsch. The loan bears interest at 4%. The loan balance at March 31,
2014 and
December 31, 2013,
respectively
, includes accrued interest payable of $355,317 and $349,466.
|
$ | 578,514 | $ | 566,399 | ||||
A loan from Paul Reid, the former President of ReceptoPharm bearing interest at a rate of 5% per annum, due on demand and secured by certain intellectual property of ReceptoPharm having a zero cost at March 31, 2014 and December 31, 2013. The accrued interest at March 31, 2014 and December 31, 2013 was $44,882 and $43,363, respectively.
|
124,708 | 123,189 | ||||||
Ending balances
|
$ | 703,222 | $ | 689,588 | ||||
March 31, 2014
|
December 31, 2013
|
|||||||
Note payable – Related Party (1)
|
$ | 180,000 | $ | 180,000 | ||||
Notes payable – Non Related Parties (2)
|
412,182 | 412,182 | ||||||
Convertible notes payable-short term, at fair value (3)
|
415,340 | 767,056 | ||||||
Convertible notes payable-long term, at fair value (4)
|
41,474 | - | ||||||
Ending balances
|
$ | 1,048,996 | $ | 1,359,238 |
(1)
|
During the third quarter of 2010 we borrowed $200,000 from one of our directors. We repaid $10,000 each (total $20,000) during the third quarter of 2012 and 2013. Under the terms of the loan agreement, this loan was expected to be repaid in nine months to a year from the date of the loan along with interest calculated at 10% for the first month plus 12% after 30 days from funding. We are in default regarding this loan. At March 31, 2014, we owed this director accrued interest of $130,262.
|
(2)
|
At March 31, 2014, the balance of $412,182 consisted of the following loans:
|
·
|
In July 2013, the Company issued a promissory note to the Michael McDonald Trust in the amount of $75,000 bearing interest at a rate of 2% per month. The note
was
due in six months from the execution and funding of the note. In connection with the issuance of this promissory note, the Company issued 1,000,000 shares of the Company's common
stock
(See note
5).
The Company has recorded a debt discount in the amount of $3,977 to reflect the value of the common stocks as a reduction to the carrying amount of the convertible debt and a corresponding increase to common stocks and additional paid-in capital. The total discount of $3,977 was fully amortized over the term of the debt at December 31, 2013. We are in default regarding this loan.
An
additional 1,000,000 shares were issued in January 2014 with a fair value at $9,900 (See
Note 5
) due to the default. At March 31, 2014, we owed Michael McDonald accrued interest of $13,500.
|
·
|
On August 2, 2011 under a settlement agreement with Liquid Packaging Resources, Inc. (“LPR”), the Company agreed to pay LPR a total of $350,000 in monthly installments of $50,000 beginning August 15, 2011 and ending on February 15, 2012. This settlement amount was recorded as general and administrative expenses on the date of the settlement. We did not make the December 2011 or January 2012 payments and on January 26, 2012, we signed the first amendment to the settlement agreement where under we agreed to pay $175,000 which was the balance outstanding at December 31, 2011(this includes a $25,000 penalty for non-payment). The Company repaid $25,000 during the three months ended March 31, 2012. The Company did not make all of the payments under such amendment and as a result pursuant to the original settlement agreement, LPR had the right to sell 5,714,326 shares of the Company’s free trading stock held in escrow by their attorney and receive cash settlements for a total amount of $450,000 (the initial $350,000 plus total default penalties of $100,000). The $100,000 default was expensed during 2012. LPR sold the note to Southridge Partners, LLP (“Southridge”) for consideration of $281,772 in October 2012. The debt has reverted back to the Company (See note 7).
|
·
|
As of March 31, 2014, the Company owed
University Centre West Ltd
. approximately $55,410, which was assigned and sold to Southridge and subsequently reverted back to the Company .
|
(3)
|
At March 31, 2014, the balance of $415,340 consisted of the following short term convertible loans:
|
·
|
In September and October 2011, the Company borrowed $250,000 each (aggregating $500,000) from two non-related parties. The principal of these loans were to be repaid with a balloon payment on or before October 1, 2012. On October 19, 2012 the parties amended the notes to extend the due date to May 1, 2013 and include a conversion feature that would allow the holders to convert some or all of their outstanding notes into restricted Company stock at a 15% discount to the average closing market price of the Company's stock traded over the previous 10 days. Interest on these loans is payable monthly beginning in November 2011 with interest calculated at 20% and 12%, each, respectively. At March 31, 2014, the accrued interest payable was $6,664.
During year ended December 31, 2013, one of the Note holders made conversions of a total of 34,254,004 shares of the company’s restricted stock satisfying the notes in the amount of $125,000 with a fair value of $317,391 on the date of conversion. During August and September, 2013, $150,000 of the debts were assigned to three non-related parties in the form of a Convertible Redeemable Note bearing interest of 8% annum with a conversion price for each share of Common Stock equal to 55% of the average of the daily volume weighted average prices of the Common Stock for the 3 trading days with the lowest volume weighted average prices during the 15 to 20 trading days immediately preceding the Conversion Date. Following the assignments, the conversions for a total of 64,052,862 shares of the company’s restricted stock were made in satisfying the notes of $150,000 at the fair value of $475,519 (See
note 5
). The maturity
date
of the two convertible notes payable of $75,000 and $150,000 were amended to May 3, 2014 and August 3, 2014, respectively. On April 30, 2014, the maturity date of May 3, 2014 was further amended to November 3, 2014. The Company issued a total of 500,000 restricted shares to the note holder in connection with the amendment at a fair value of $1,950 (See note 8).
At March 31, 2014, the remaining balance of these two convertible notes payable of $75,000 and $150,000 were recorded at a fair value of $84,650 and $177,033, respectively.
|
·
|
On July 10, 2013, the Company issued a Convertible Debentures in the amount of $30,000 to Christopher Castaldo in connection with the agreement for investor relation services. The note carries interest at 8% and is due on January 10, 2014. The note’s holder has the right to convert the note and accrued interest into shares of Common Stock at a price of $0.005. The Company continued to accrue the interest at 8% after the note was in default. On February 26, 2014, the conversion for a total of 6,000,000 shares of the company’s restricted stock was made in satisfying the note in full with a fair value of $51,060 (See Note 5).
|
·
|
On October 10, 2013, the Company issued a Convertible Debentures in the amount of $30,000 to Christopher Castaldo in connection with the agreement for investor relation services. The note carries interest at 8% and is due on April 10, 2014. The note’s holder has the right to convert the note into shares of Common Stock at a price of $0.005. The Note for $30,000 is currently in default. At March 31, 2014, the convertible note payable, at fair value, was recorded at $38,466.
|
·
|
On September 3, 2013, the Company issued a Convertible Debenture in the amount of $100,000 to Coventry Enterprises, LLC (“Coventry”). The note carries interest at 10% and is due on September 3, 2014, unless previously converted into shares of restricted common stock. Coventry has the right to convert the note, until is no longer outstanding into shares of Common Stock at a price lesser of $.018, or (ii) fifty-five percent (55%) of the average of the three lowest VWAP prices of the Company’s Common Stock for the twenty trading days preceding the conversion date. Coventry made
a
conversion
of
a total of
23,376,623 shares of the company’s restricted stock satisfying $90,000 of the notes with a fair value of $187,119 on March 11, 2014 (See note 5). At March 31, 2014, the remaining balance of the convertible note payable of $10,000, at fair value, was recorded at $17,754.
I
n connection with the issuances of the Note, the Company also granted five-year warrants to purchase an aggregate of 20,000,000 shares of the Company’s common stock at an exercise price of $0.025 per share. The Company classified embedded conversion features in these warrants as a derivative liability. The warrants were valued at their fair value of $112,118 using the Black-Scholes method at the March 31, 2014.
|
·
|
On September 12, 2013, the Company issued a Convertible Debenture in the amount of $70,000 to Coventry Enterprises, LLC (“Coventry”). The note carries interest at 10% and is due on September 12, 2014, unless previously converted into shares of restricted common stock. Coventry has the right to convert the note, until is no longer outstanding into shares of Common Stock at a price lesser of $.02, or (ii) fifty-five percent (55%) of the average of the three lowest VWAP prices of the Company’s Common Stock for the twenty trading days preceding the conversion date. Coventry
made
a
conversion
of
a total
of 15,584,415 shares of the company’s restricted stock satisfying $60,000 of the notes with a fair value of $123,641 on March 12, 2014 (See note 5). At March 31, 2014, the remaining balance of the convertible note payable of $10,000, at fair value, was recorded at $17,774.
In connection with the issuances of the Note, the Company also granted five-year warrants to purchase an aggregate of 15,000,000 shares of the Company’s common stock at an exercise price of $0.025 per share. The Company classified embedded conversion features in these warrants as a derivative liability. The warrants were valued at their fair value of $84,221 using the Black-Scholes method at March 31, 2014.
|
·
|
On October 7, 2013, the Company signed a secured convertible Promissory Note in the amount of $35,000 in favor of Southridge Partners II, LLC. The note was due on demand and carries interest at 10% annum. Southridge Partners II, LLC was entitled to convert the principal into shares of common stock at the lesser of $0.015 or a 50% discount from the lowest closing bid price in the 30 trading days prior to the day that the conversion is requested; and interest accrued was entitled to convert into shares of common stock at $0.001. In the evaluation of these financing arrangements, the Company concluded that these conversion features did not meet the conditions set forth in current accounting standards for equity classification. Since equity classification is not available for the conversion feature, it requires bifurcation and liability classification, at fair value. The Company also concluded that the Default Put required bifurcation because, while puts on debt instruments are generally considered clearly and closely related to the host, the Default Put is indexed to certain events that are not associated with the convertible note payable. At March 31, 2014, this convertible note payable, at fair value, was recorded at $79,663. Southridge converted the note in full for a total of 13,349,057 shares of the company’s restricted stock on April 7, 2014 (See note 8).
|
(4)
|
On March 19, 2014, the Company issued two Convertible Debentures in the
amount of
up to
$500,000 each (total $1,000,000) to two non-related parties
. During the three months ended March 31, 2014, the Company recorded the first tranche of
$15,000 each (total $30,000) of the funds was received during the first quarter of 2014. The notes carry interest at 8% and are due on the date that is two years from the execution and funding of the note. The
note
holders have the right to convert the notes into shares of Common Stock at a price of $0.005. In connection with the issuance of these convertible notes payable, the Company encountered a day-one derivative loss of $18,104. At March 31, 2014, these convertible notes payable, at fair value, was recorded at $41,474.
|
Date
|
Number of shares converted
|
Fair Value of Debt Converted
|
||||||
March 11, 2014
|
23,376,623 | $ | 187,119 | |||||
March 12, 2014
|
15,584,415 | $ | 123,641 | |||||
Number of shares
|
Weighted average exercise price
|
|||||||
Balance December 31, 2013
|
154,916,667 | $ | 0.082 | |||||
Exercised
|
- | - | ||||||
Issued
|
12,000,000 | $ | 0.03 | |||||
Forfeited
|
- | - | ||||||
Balance March 31, 2014
|
166,916,667 | $ | 0.064 |
Weighted
|
|||||||||||||
Average
|
Weighted
|
||||||||||||
Number
|
Contractual
|
Average
|
|||||||||||
Exercise Price
|
Outstanding
|
Life
|
Exercise Price
|
||||||||||
|
1.72 | ||||||||||||
2014
|
$
|
0.01-0.10
|
166,916,667
|
years
|
$
|
0.064
|
·
|
Cobroxin
®
, an over the counter pain reliever designed to treat moderate to severe (Stage 2) chronic pain; and
|
|
|
·
|
Nyloxin
®
(Stage 2 Pain)
|
|
● | Nyloxin ® Extra Strength (Stage 3 Pain). |
·
|
safe and effective;
|
|
·
|
all natural;
|
·
|
long-acting;
|
·
|
easy to use;
|
·
|
non-narcotic;
|
·
|
non-addictive; and
|
·
|
analgesic and anti-inflammatory.
|
·
|
Topical Gel: 30 mcg/mL
|
·
|
Oral Spray: 70 mcg/mL
|
·
|
Topical Gel: 60 mcg/mL
|
·
|
Oral Spray: 140 mcg/mL
|
·
|
Topical Gel: 20 mcg/mL
|
·
|
Oral Spray: 35 mcg/mL
|
¨
|
whether Cobroxin
®
, Nyloxin
®
, and Nyloxin
®
Extra Strength will be accepted by retail establishments where they are sold;
|
|
|
¨
|
because Cobroxin
®
is a novel approach to the over-the-counter pain market, whether it will be accepted by consumers over conventional over-the-counter pain products;
|
|
|
|
|
¨
|
whether our international drug applications will be approved and in how many countries;
|
|
|
¨
|
whether we will be successful in marketing Cobroxin
®
, Nyloxin
®
and Nyloxin
®
Extra Strength in our target markets and create nationwide and international visibility for our products;
|
|
|
¨
|
whether our drug delivery system, i.e. oral spray and gel, will be accepted by consumers who may prefer a pain pill delivery system;
|
|
|
¨
|
whether competitors’ pain products will be found to be more attractive to consumers;
|
|
|
¨
|
whether we successfully develop and commercialize products from our research and development activities;
|
|
|
¨
|
whether we compete effectively in the intensely competitive biotechnology area;
|
|
|
¨
|
whether we successfully execute our planned partnering and out-licensing products or technologies;
|
|
|
¨
|
whether the current economic downturn and related credit and financial market crisis will adversely affect our ability to obtain financing, conduct our operations and realize opportunities to successfully bring our technologies to market;
|
|
|
¨
|
whether we are subject to litigation and related costs in connection with use of products;
|
|
|
¨
|
whether we will successfully contract with domestic distributor(s)/advertiser(s) for our products and whether that will cause interruptions in our operations;
|
|
|
¨
|
whether we comply with FDA and other extensive legal/regulatory requirements affecting the healthcare industry.
|
|
|
¨
|
An obligation under a guarantee contract.
|
|
|
¨
|
A retained or contingent interest in assets transferred to the unconsolidated entity or similar arrangement that serves as credit, liquidity or market risk support to such entity for such assets.
|
|
|
¨
|
Any obligation, including a contingent obligation, under a contract that would be accounted for as a derivative instrument.
|
|
|
¨
|
Any obligation, including a contingent obligation, arising out of a variable interest in an unconsolidated entity that is held by us and material to us where such entity provides financing, liquidity, market risk or credit risk support to, or engages in leasing, hedging or research and development services with us.
|
Exhibit No.
|
Title
|
|
31.1
|
Certification of Chief Executive Officer and Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
|
|
32.1
|
Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
|
NUTRA PHARMA CORP.
|
|
Registrant
|
|
Dated: May 20, 2014
|
/s/ Rik J. Deitsch
|
Rik J. Deitsch
|
|
Chief Executive Officer/Chief Financial Officer
|
1 Year Nutra Pharma (CE) Chart |
1 Month Nutra Pharma (CE) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions